The potential of newer immunomodulating drugs in the treatment of uveitis: a review

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
J Salzmann, S L Lightman


Uveitis, or intraocular inflammation, remains an ongoing challenge to ophthalmologists and patients alike. In most patients, uveitis is limited to the anterior ocular structures and is readily managed with topical steroids. The inflammatory process can extend behind the lens to involve the pars plana, the vitreous cavity, the choroid and the retina. These intermediate and posterior uveitides are relatively rare but contribute disproportionately to visual morbidity and present serious diagnostic and therapeutic difficulties. Systemic steroids constitute the first line of treatment for most sight-threatening uveitides. Their long term use is limited by universal and debilitating adverse effects. Second-line, steroid-sparing agents allow a reduction in steroid dosage. Cyclosporin and azathioprine are the main steroid-sparing agents currently in use. However, these compounds are limited by a narrow therapeutic window and significant adverse effects. This paper offers a brief discussion of some of the immune mechanisms involved in the pathogenesis of uveitis and reviews categories of investigational compounds. Inhibitors of T cell function: tacrolimus (previously FK506), licensed for use in liver transplantation, and sirolimus (rapa...Continue Reading


Jan 1, 1992·Annual Review of Immunology·N H Sigal, F J Dumont
Oct 1, 1992·Clinical Immunology and Immunopathology·H LuoJ Wu
Mar 1, 1992·The British Journal of Ophthalmology·A RothovaA Kijlstra
Jul 1, 1991·Current Eye Research·Y FujinoR B Nussenblatt
Feb 1, 1991·Scandinavian Journal of Immunology·E M EuguiA C Allison
Oct 1, 1990·International Ophthalmology·R B Nussenblatt
Dec 1, 1987·Journal of the American Academy of Dermatology·W W EpinetteM C Greist
Jun 1, 1986·World Journal of Surgery·B D KahanC T Van Buren
Feb 15, 1987·American Journal of Ophthalmology·E Bloch-Michel, R B Nussenblatt
Aug 1, 1982·American Journal of Ophthalmology·R B NussenblattA E Maumenee
Jan 1, 1993·Immunologic Research·R LahesmaaP Toivanen
Dec 15, 1994·American Journal of Ophthalmology·M IshiokaS Tanaka
Jun 15, 1993·American Journal of Ophthalmology·M MochizukiG Inaba
Oct 1, 1994·Agents and Actions·S M Robertson, L S Lang
Jan 1, 1993·Springer Seminars in Immunopathology·R R BartlettR Schleyerbach
Mar 1, 1993·Clinical and Experimental Rheumatology·R P CarlsonA J Lewis
Jun 23, 1993·Annals of the New York Academy of Sciences·S N Sehgal, C C Bansbach
Apr 9, 1993·Cell·T Taniguchi, Y Minami
Dec 1, 1995·Therapeutic Drug Monitoring·J T Ransom
Feb 27, 1996·Transplantation·K F SiemaskoA Finnegan
Nov 16, 1996·Lancet·J J Lipsky
Sep 1, 1996·The British Journal of Ophthalmology·M S Suttorp-Schulten, A Rothova
Feb 1, 1997·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·K A Hood, D G Zarembski
Feb 22, 1997·Lancet·M BöhmT Luger
Jan 1, 1997·Annual Review of Immunology·S L Constant, K Bottomly

❮ Previous
Next ❯

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie
Kirsten SiepmannManfred Zierhut
International Ophthalmology Clinics
Carl P HerbortMarina Papadia
Investigative Ophthalmology & Visual Science
Guey-Shuang WuNarsing A Rao
© 2021 Meta ULC. All rights reserved